Cargando…

Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma

Except for the traditional chemotherapy, few treatments strategy about miliary intrapulmonary carcinomatosis (MIPC) have been reported in the existing literature. In this report, we primarily discussed the possible etiology and the potentially effective treatment options for a patient with MIPC who...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jian, Xu, Ya, Huang, Wen-Cai, Ji, Tao, Ai, Guo-Ping, Gao, Yan-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293051/
https://www.ncbi.nlm.nih.gov/pubmed/35860549
http://dx.doi.org/10.3389/fonc.2022.922076
_version_ 1784749525229895680
author Zhu, Jian
Xu, Ya
Huang, Wen-Cai
Ji, Tao
Ai, Guo-Ping
Gao, Yan-Hong
author_facet Zhu, Jian
Xu, Ya
Huang, Wen-Cai
Ji, Tao
Ai, Guo-Ping
Gao, Yan-Hong
author_sort Zhu, Jian
collection PubMed
description Except for the traditional chemotherapy, few treatments strategy about miliary intrapulmonary carcinomatosis (MIPC) have been reported in the existing literature. In this report, we primarily discussed the possible etiology and the potentially effective treatment options for a patient with MIPC who benefited from combined treatment. A nonsmoking woman was diagnosed with MIPC at an advanced stage. Gene detection showed an EGFR negative status. She accepted first-line chemotherapy with pemetrexed and cisplatin, and the tumor progressed. Next, PD-1 inhibitors plus pemetrexed and cisplatin were administered, and the tumor remained uncontrolled. After two cycles of recombinant human endostatin plus second-line chemotherapy, the numerous pulmonary nodules had all nearly completely disappeared, while an accentuated decrease in the primary tumor volume was observed. Moreover, biochemical markers, including the patient’s tumor markers, also trended toward normal. This report describes the first case of a MIPC patient who significantly responded to antiangiogenic therapy combined with chemotherapy. Anti-angiogenic therapy may be a possible strategy for the EGFR-negative lung adenocarcinoma population.
format Online
Article
Text
id pubmed-9293051
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92930512022-07-19 Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma Zhu, Jian Xu, Ya Huang, Wen-Cai Ji, Tao Ai, Guo-Ping Gao, Yan-Hong Front Oncol Oncology Except for the traditional chemotherapy, few treatments strategy about miliary intrapulmonary carcinomatosis (MIPC) have been reported in the existing literature. In this report, we primarily discussed the possible etiology and the potentially effective treatment options for a patient with MIPC who benefited from combined treatment. A nonsmoking woman was diagnosed with MIPC at an advanced stage. Gene detection showed an EGFR negative status. She accepted first-line chemotherapy with pemetrexed and cisplatin, and the tumor progressed. Next, PD-1 inhibitors plus pemetrexed and cisplatin were administered, and the tumor remained uncontrolled. After two cycles of recombinant human endostatin plus second-line chemotherapy, the numerous pulmonary nodules had all nearly completely disappeared, while an accentuated decrease in the primary tumor volume was observed. Moreover, biochemical markers, including the patient’s tumor markers, also trended toward normal. This report describes the first case of a MIPC patient who significantly responded to antiangiogenic therapy combined with chemotherapy. Anti-angiogenic therapy may be a possible strategy for the EGFR-negative lung adenocarcinoma population. Frontiers Media S.A. 2022-07-04 /pmc/articles/PMC9293051/ /pubmed/35860549 http://dx.doi.org/10.3389/fonc.2022.922076 Text en Copyright © 2022 Zhu, Xu, Huang, Ji, Ai and Gao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhu, Jian
Xu, Ya
Huang, Wen-Cai
Ji, Tao
Ai, Guo-Ping
Gao, Yan-Hong
Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma
title Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma
title_full Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma
title_fullStr Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma
title_full_unstemmed Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma
title_short Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma
title_sort case report: recombinant human endostatin plus chemotherapy for epidermal growth factor receptor-negative miliary lung adenocarcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293051/
https://www.ncbi.nlm.nih.gov/pubmed/35860549
http://dx.doi.org/10.3389/fonc.2022.922076
work_keys_str_mv AT zhujian casereportrecombinanthumanendostatinpluschemotherapyforepidermalgrowthfactorreceptornegativemiliarylungadenocarcinoma
AT xuya casereportrecombinanthumanendostatinpluschemotherapyforepidermalgrowthfactorreceptornegativemiliarylungadenocarcinoma
AT huangwencai casereportrecombinanthumanendostatinpluschemotherapyforepidermalgrowthfactorreceptornegativemiliarylungadenocarcinoma
AT jitao casereportrecombinanthumanendostatinpluschemotherapyforepidermalgrowthfactorreceptornegativemiliarylungadenocarcinoma
AT aiguoping casereportrecombinanthumanendostatinpluschemotherapyforepidermalgrowthfactorreceptornegativemiliarylungadenocarcinoma
AT gaoyanhong casereportrecombinanthumanendostatinpluschemotherapyforepidermalgrowthfactorreceptornegativemiliarylungadenocarcinoma